STOCK TITAN

Acelrx Pharmaceuticals Inc - ACRX STOCK NEWS

Welcome to our dedicated news page for Acelrx Pharmaceuticals (Ticker: ACRX), a resource for investors and traders seeking the latest updates and insights on Acelrx Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Acelrx Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Acelrx Pharmaceuticals's position in the market.

Rhea-AI Summary
AcelRx Pharmaceuticals, Inc. changes its name to Talphera, Inc. with a focus on developing and commercializing innovative therapies for medically supervised settings. The company's lead product candidate, Niyad, has been granted FDA Breakthrough Designation and is expected to have a Premarket Approval (PMA) submission to the FDA in the second half of 2024. Talphera will commence trading on the Nasdaq Global Market under the ticker symbol 'TLPH' effective January 10, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.5%
Tags
none
-
Rhea-AI Summary
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) published a study on U.S. physician anticoagulation use during continuous renal replacement therapy (CRRT) in patients with acute kidney injury. The study reveals increased CRRT machine use, with heparin being used in 43% of patients, citrate in 28%, and no anticoagulation in 29%. Concerns with heparin include systemic bleeding and thrombocytopenia, while citrate usage is hindered by hypocalcemia and safety issues. The study highlights the need for a new regional anticoagulant for patients intolerant to heparin, potentially improving the quality of CRRT for these patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.46%
Tags
none
-
Rhea-AI Summary
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) achieved FDA Investigational Device Exemption (IDE) approval for Niyad™ in the third quarter. The company plans to start its Niyad registrational study this quarter and expects topline data by mid-2024. They also have cash and investments of $13.4 million as of September 30, 2023, with a new financing round providing up to $26.3 million. A Key Opinion Leader panel discussion on Niyad is planned for December 6th.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.32%
Tags
earnings
Rhea-AI Summary
AcelRx Pharmaceuticals, Inc. (ACRX) to host virtual KOL panel discussion on Niyad anticoagulant for dialysis circuits. Discussion includes recent market research and NEPHRO CRRT study. Register for the webcast event on December 6, 2023 at 11:00 a.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.92%
Tags
conferences clinical trial
-
Rhea-AI Summary
AcelRx Pharmaceuticals will release its third quarter 2023 financial results on November 8th and host a webcast and conference call to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.85%
Tags
conferences earnings
-
Rhea-AI Summary
AcelRx Pharmaceuticals receives FDA approval for pivotal study of Niyad™, the first regional anticoagulant for extracorporeal circuit in the US
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.64%
Tags
none
Rhea-AI Summary
AcelRx Pharmaceuticals CEO to present at H.C. Wainwright Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.02%
Tags
conferences
-
Rhea-AI Summary
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) reported its Q2 2023 financial results and corporate update. The company closed a capital raise in July, led by new healthcare investors, providing access to up to $26.3 million. AcelRx awaits an FDA response to Emergency Use Authorization of Niyad submitted in April, with a registrational study set to initiate in Q4 2023. The company fully repaid senior debt with Oxford in Q2 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
earnings
-
Rhea-AI Summary
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) will release its second quarter 2023 financial results after market close on August 10, 2023. The company will host a live webcast and conference call at 4:30 p.m. EDT/1:30 p.m. PDT to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.13%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.67%
Tags
none
Acelrx Pharmaceuticals Inc

Nasdaq:ACRX

ACRX Rankings

ACRX Stock Data

14.58M
12.03M
2.64%
38.89%
3%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Redwood City

About ACRX

acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v